Wednesday, June 05, 2019 10:59:46 AM
June 5, 2019 News
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer’s disease among world’s leading researchers
TORONTO, Ontario and CAMBRIDGE, Mass. —June 5, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer’s disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world’s most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care. ProMIS’ Chief Development Officer Dr. Johanne Kaplan will present the company’s lead therapeutic candidate PMN310 which demonstrates high selectivity for the toxic forms of amyloid beta implicated as a root cause of Alzheimer’s disease.
In the poster, “Selective targeting of HHQK conformational epitope in amyloid-beta oligomer species by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease,” Dr. Kaplan will present data for PMN310 that show:
Superior selectivity for amyloid beta (AßOs) toxic oligomers.
Potential to safely administer high doses of PMN310 with a reduced risk of brain swelling or ARIA.
Potential to show greater therapeutic potency compared with other Aß-directed antibodies.
“Evidence continues to mount, showing that amyloid-beta toxic oligomers (AßO) – not amyloid plaque – are the key target for Alzheimer’s disease therapy,” said Dr. Johanne Kaplan. “The current therapeutic gap lies in how to effectively neutralize the toxic oligomer without wasting antibody on non-toxic forms of the protein. We’re pleased our data will help inform discussions regarding future directions among the world’s most accomplished researchers. Our data will demonstrate the unique ability of the ProMIS discovery platform to generate antibodies that bind the toxic species of amyloid beta while preserving healthy forms of the protein. Humanized PMN310 is currently in advanced preclinical development.”
The conference, Keystone Symposia on Molecular and Cellular Biology, Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, takes place on June 16-20, 2019 at Keystone Resort in Keystone, Colorado. For more information, please visit www.keystonesymposia.org.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn and listen to the podcast, Saving Minds, at iTunes or Spotify.
Recent PMN News
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS • GlobeNewswire Inc. • 04/09/2024 11:00:00 AM
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 04/01/2024 08:15:00 PM
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- ProMIS Neurosciences Issues Letter to Shareholders • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- ProMIS Neurosciences, Inc. Announces Leadership Transition • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- ProMIS Neurosciences Announces Publication on Novel Target for ALS • GlobeNewswire Inc. • 12/20/2023 12:00:00 PM
- ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease • GlobeNewswire Inc. • 11/20/2023 12:00:00 PM
- ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- ProMIS Neurosciences Closes $20.4 Million Private Placement Financing • GlobeNewswire Inc. • 09/08/2023 11:00:00 AM
- ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 04:18:53 PM
- ProMIS Neurosciences Announces $20.4 Million Private Placement Financing • GlobeNewswire Inc. • 08/21/2023 08:12:03 PM
- ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 08/14/2023 09:33:19 PM
- ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline • GlobeNewswire Inc. • 07/17/2023 11:00:00 AM
- ProMIS Announces Completion of Continuance • GlobeNewswire Inc. • 07/14/2023 11:45:00 AM
- ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange • GlobeNewswire Inc. • 07/10/2023 11:55:00 AM
- ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved • GlobeNewswire Inc. • 06/30/2023 12:00:00 PM
- Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time • GlobeNewswire Inc. • 06/29/2023 12:00:00 PM
- ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 05/15/2023 09:00:00 PM
- ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease • GlobeNewswire Inc. • 05/08/2023 01:00:00 PM
- Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease • GlobeNewswire Inc. • 04/25/2023 09:00:00 PM
- ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting • GlobeNewswire Inc. • 04/24/2023 11:30:00 AM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM